Atossa Genetics Announces Intraductal Microcatheter

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
77
Atossa Genetics Announces Intraductal Microcatheter ImmunoOncology Pre-Clinical Program

SEATTLE, July 18, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it is advancing its intraductal microcatheter immunotherapy program with pre-clinical studies being conducted by Translational Drug Development, LLC (“TD2”). The purpose of the initial study is to develop and validate preclinical methods of using Atossa’s proprietary intraductal microcatheter technology to administer immunotherapy to the site of tumor initiation.  

“While there has been recent success treating blood cancers with chimeric antigen receptor therapy (or, CAR-T), there has not been much success using CAR-T to treat solid tumors like breast cancer,” commented Steve Quay, Ph.D., MD, President and CEO of Atossa. “We are, however, encouraged by a recent case study reported June 4, 2018 in Nature Medicine (N. Zacharakis, et al.), in which a patient with metastatic breast cancer who was not responding to chemotherapy had complete tumor regression 22 months after being treated with an intravenous infusion of eighty billion T-cells and interleukin. We believe our proprietary intraductal microcatheter technology may provide a unique and more efficacious and cost-effective treatment method by delivering a significantly smaller number of T-cells directly to the site of the cancer prior to metastasis, rather than through the blood stream, where they are diluted into the entire body. These studies are the first of several steps to develop our intraductal microcatheter technology to treat breast cancer with cell-based immunotherapy, such as CAR-T. These pre-clinical studies will form the basis for the design of human studies, with the ultimate goal of treating breast cancer by administering an immunotherapy with our proprietary microcatheter technology,” added Dr. Quay. 

The studies are being conducted for Atossa by Translational Drug Development, LLC, which is an oncology development organization that provides innovative services and is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases.

About Atossa Genetics

Atossa Genetics Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com .

About TD2

TD2 supports oncology-focused companies by providing a unique and translational set of services to accelerate drug development.  Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 applies thorough and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. For more information, visit www.TD2inc.com .

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, potential market sizes for Atossa’s drugs under development and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Atossa Genetics Company Contact:

Atossa Genetics Inc. Kyle Guse CFO and General Counsel (O) 866 893-4927 kyle.guse@atossagenetics.com

Investor Relations Contact:

Scott Gordon CoreIR 377 Oak Street Concourse 2 Garden City, NY 11530 Office: 516 222-2560 scottg@CoreIR.com

Source: Atossa Genetics Inc.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 210

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 279

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 305

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 269

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 164

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 349

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 266

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 176

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 377

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 59

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading

Top 5 Most Recently Viewed Articles

Flora Growth Corp Sees 6% Surge in After-Hours Performance

Updated Category News Views 87

A Surge in After-Hours Trading for Flora Growth Corp Flora Growth Corp. (NASDAQ: FLGC) recently demonstrated significant volatility by surging 5.98% to $10.55 during after-hours trading. This movement came not long after closing at $9.96, which marked an increase of 3.59% earlier that day. Insights from Recent SEC Filing Regulation A Filing In a notable move, Flora Growth...

Continue Reading
Qubs Introduces Qubitunes, A New Interactive Audio Experience

Updated Category News Views 205

Qubs Launches Qubitunes for Creative Play Qubs has unveiled an exciting new product, Qubitunes, which has already won the 'Top Toy' award in the startup category at a prestigious Toy Fair. This innovative toy is set to transform playtime for children by offering a unique platform where they can express their creativity and dive into their own audio storytelling...

Continue Reading
Asyad Group's Expert Transport of Heavy Cryogenic Tank

Updated Category News Views 126

Asyad Group's Successful Transport of Cryogenic Tank Asyad Group has recently completed a remarkable international transport operation, successfully moving a 115 metric ton pressurized cryogenic tank from Northern India to a major destination in Saudi Arabia. This endeavor highlights the Group's expertise in cross-border logistics. A Journey of Precision The transport...

Continue Reading
Famous Toastery Launches Holiday Fundraising Efforts

Updated Category News Views 134

Famous Toastery's Compassionate Campaign for Local Communities The Famous Toastery, known for its delightful breakfast and brunch offerings, is stepping up this holiday season with a noble initiative aimed at fighting hunger. This renowned franchise is collaborating with Feeding the Carolinas, encouraging guests to make donations that will significantly impact individuals...

Continue Reading
Jiayin Group's Upcoming Earnings Call Set for November 25, 2025

Updated Category News Views 190

Jiayin Group Inc. Announces Q3 2025 Financial Results Release Jiayin Group Inc. (NASDAQ: JFIN), a prominent fintech platform in China, has shared significant news that it will unveil its unaudited financial outcomes for the third quarter of 2025. This crucial announcement is set to occur before the U.S. markets open on November 25, 2025. The anticipation surrounding these...

Continue Reading